












462Correlation of pre-existing radial artery
macrocalciﬁcations with late patency of primary
radiocephalic ﬁstulas in diabetic hemodialysis
patients
George S. Georgiadis, MD,a Efstratios I. Georgakarakos, MD,a George A. Antoniou, MD,a
Stelios Panagoutsos, MD,b Christos Argyriou, MD,a Efthimia Mourvati, MD,b Ploumis Passadakis, MD,b
and Miltos K. Lazarides, MD, EBQSvasc,a Alexandroupolis, Greece
Objective: The aim of this study was to evaluate the impact of pre-existing radial artery macrocalciﬁcation (Mönckeberg
type of arteriosclerosis) on patency rates of radiocephalic ﬁstulas (RCFs) in diabetic end-stage renal disease (ESRD)
patients undergoing hemodialysis.
Methods: In this observational prospective study, the long-term patency rates (primary outcome measures) of RCFs in
ESRD diabetics who had Mönckeberg radial (6brachial) artery disease (calciﬁed [C] group) were compared with those
obtained in ESRD diabetics who had healthy, noncalciﬁed vessels before RCF construction (healthy [H] group). Vessel
calciﬁcation was assessed by plain two-dimensional radiography. For inclusion in the C-group, uniform linear railroad
track-type macrocalciﬁcations of at least 6 cm in length, in the medial wall of the radial artery ipsilateral to RCF creation,
were required. Patients were included in the H-group if the radial artery ipsilateral to the RCF creation was free of any
macrocalciﬁcation, of either intima or media type. Any intimal-like plaque with irregular and patchy distribution was an
exclusion criterion for both groups. Patients in both groups also were required to have suitable upper limb vascular
anatomy on the basis of ultrasound imaging before RCF creation (cephalic vein of minimum diameter of 1.6 mm, without
stenosis or thrombosis in all outﬂow areas, and radial artery of minimum diameter of 1.5 mm, without proximal
hemodynamically signiﬁcant stenosis). Secondary outcome measures included all-cause mortality. Kaplan-Meier statistics
were used for comparison between groups.
Results: The arm radiograph at the site of possible ﬁstula construction showed abnormality in 39 patients (C-group, 47
RCFs), whereas 33 patients had noncalciﬁed (“healthy”) vascular anatomy (H-group, 40 RCFs). Mean duration of the
diabetic disease at the time of RCF creation was 8.9 6 5.6 years (range, 2-25 years) for the H-group and 14 6 9.9 years
(range, 1-40 years) for the C-group (P [ .018). The mean follow-up period for H-group and C-group was 51.9 6
35.9 months (range, 0.1-126 months) and 26.1 6 31.6 months (range, 0.1-144 months), respectively (P [ .0006).
Forty-four patients died during the follow-up period. Primary patency rates at 12, 24, 36, and 48 months for C-group vs
H-group were 50.2% vs 80%, 36.5% vs 72.3%, 32.4% vs 67.9%, and 29.1% vs 59.3% (P [ .0019). Respective values for
secondary patency rates were 52.4% vs 87.5%, 40.9% vs 82.4%, 36.6% vs 78.1%, and 33.2% vs 72.8% (P[ .00064). Patient
survival rates at 24 and 48 months were 56.1% and 46.4% for C-group and 92.4% and 67.4% for H-group, respectively
(P [ .05).
Conclusions: ESRD diabetics with radial artery Mönckeberg calciﬁcations receiving RCFs had worse late clinical outcomes
compared with ESRD diabetics with healthy distal arm vessels receiving the same access. The long-term beneﬁt of RCFs
may be lost in diabetics with extensively calciﬁed vessels, and preferably the brachial artery should be used instead. (J Vasc
Surg 2014;60:462-70.)Autogenous arteriovenous ﬁstulas remain the ﬁrst
choice for hemodialysis patients, with superior outcomes
compared with prosthetic grafts.1 However, lower patency
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://dx.doi.org/10.1016/j.jvs.2014.02.042been reported in radiocephalic ﬁstulas (RCFs) in speciﬁc
populations, like diabetics and elder patients.2,3 Part of
this high failure rate, especially early thrombosis, has been
attributed to the high calciﬁed burden in the forearm
arteries as a result of Mönckeberg disease, which leads to
insufﬁcient ﬁstula blood volume, the prerequisite for
venous dilation and satisfactory blood ﬂow.3 Mönckeberg
medial calciﬁcation, a feature of peripheral arterial disease,
is frequent in older individuals, end-stage renal disease
(ESRD), autonomic neuropathy, and diabetes mellitus.4,5
It has been characterized as a noninﬂammatory degenera-
tive disease in which the media of small and medium-
sized muscle-type conduit arteries, such as radial, femoral,
and tibial arteries, becomes calciﬁed independently of
atherosclerosis. There is no involvement of the intima layer
Fig 1. Plain radiograph of a C-group patient with end-stage renal
disease (ESRD) demonstrating the characteristic “railroad track”
pattern of radial artery media wall calciﬁcation (Mönckeberg
disease).
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rigid medial wall, and luminal narrowing is not a direct
consequence (Fig 1). Arterial medial calciﬁcation or Mön-
ckeberg type of arteriosclerosis (medial sclerosis) is discrete
from arterial intimal calciﬁcation, which is associated with
the development of plaques and occlusive lesions.6 The
prevalence of arteriovenous ﬁstula medial wall calciﬁcations
has been reported between 14% and 23% in hemodialysis
patients.7,8 Furthermore, radial artery media sclerosis with
medial linear macrocalciﬁcations, visible on plain radio-
graphic hand ﬁlms, is expected in about 37% of prevalent
patients treated with hemodialysis.9 Like pre-existing
medial ﬁbrosis and intimal hyperplasia,10,11 pre-existing
microcalciﬁcation may limit arterial dilation and can cause
early RCF failure, but this intrinsic vascular abnormality
has not been correlated clinically with ﬁstula patency.
The aim of this study was to evaluate the impact of pre-
existing radial artery macrocalciﬁcation on patency rates of
RCFs in diabetic hemodialysis patients. Speciﬁcally, the pri-
mary and secondary patency rates of RCFs in type 1 and
type 2 diabetics with purely Mönckeberg radial (6brachial
bifurcation) artery disease were compared with those
obtained in type 1 and type 2 diabetics who had healthy,
noncalciﬁed (of either intima or media type) vessels
before RCF construction. Patient survival rates were also
examined.
METHODS
This was a longitudinal (prospective) observational
study performed in a single referral vascular center. Per
deﬁned protocol, new ESRD diabetic (type 1 and type 2)
patients arriving in the renal replacement therapy pool
(“incident” patients) and ESRD-treated diabetic (type 1
and type 2) patients already receiving dialysis (“prevalent”
patients) were included if they had purely radial artery me-
dia wall macrocalciﬁcations of Mönckeberg type (calciﬁed
[C] group) or were free of calciﬁcations of the radial artery,
of either intima or media type (healthy [H] group), beforeRCF construction. For inclusion in either group, each dia-
betic patient was also required to have suitable arm vascular
anatomy before RCF creation (cephalic vein of minimum
diameter of 1.6 mm, without stenosis or thrombosis in
all outﬂow areas, and radial artery of minimum diameter
of 1.5 mm, without proximal hemodynamically signiﬁcant
stenosis). Macrocalciﬁcation of the radial and brachial ar-
teries was assessed by plain two-dimensional radiography
of the arm a few days before RCF construction. Radio-
graphs were analyzed independently by two experienced
physicians (vascular surgeon and nephrologist). For inclu-
sion in C-group, uniform linear railroad tracketype mac-
rocalciﬁcations in the media of the radial artery ipsilateral
to RCF creation were required. However, this angiogram-
like segment of the distal radial artery, including the anas-
tomosis area, should measure at least 6 cm in length.
Although we did not use a vascular calciﬁcation score,
the selection of a calciﬁcation pattern of at least 6 cm in
length represents a valid segment of linear calciﬁcation
outlining the vessel wall and undoubtedly has vascular
localization (includes the proximal artery, the planned
area of the anastomosis, and the distal artery). Patients
were included in H-group if the radial artery ipsilateral to
the RCF creation was free of any visible radiographic macro-
calciﬁcations, of either intima or media type. Furthermore,
no intraoperatively visible or palpable calciﬁcations had to
be recognized. Finally, any intimal-like plaque with irregular
and patchy distribution was an exclusion criterion for both
groups. Upper limb vein and arterial ultrasound imaging
preceded each RCF construction to set minimum vascular
diameters and to ensure vessel patency as described before.
Each patient gave informed written consent to participate
in the study, which was approved by our institutional review
board. Recruitment of patients was between January 2001
and January 2006 (last assessment: end of January 2013).
The primary and secondary patency rates of RCFs con-
structed in the C-group and H-group patients were
compared (primary end points). Secondary outcome mea-
sures included the patient survival rates. The duration of
primary patency was deﬁned as the period from RCF place-
ment to ﬁrst intervention or ﬁstula failure. Secondary
patency duration was deﬁned as the interval from RCF
placement to ﬁstula abandonment because of nonfunction
or occlusion (thrombosis) or the time of patency measure-
ment including intervening manipulations (surgical or
endovascular interventions) designed to reestablish func-
tionality in the thrombosed access.12 Primary patency
included death or renal transplantation with a patent
RCF. The “intent to treat” rule has been used in this report
dealing with patency of arteriovenous access.12 Excluded
from patency comparisons were only RCFs with incom-
plete follow-up data. As such, ﬁstulas that failed to mature,
ﬁstulas that were patent but not used, and ﬁstulas that
occluded before use were included in analysis.
RCF failure was considered when at least any of the
following clinical features were observed: reduced thrill or
weak bruit of auscultation; decreased ﬂow rate as deﬁned
by the National Kidney Foundation’s Kidney Disease
Table I. Patient demographics and clinical characteristicsa
Variable C-group (n ¼ 39), No. (%) H-group (n ¼ 33), No. (%) P value
Age, years, mean 6 SD (range) 62.8 6 10.5 (42-83) 65.7 6 7.5 (44-76) .17
Male gender 32 (82.1) 22 (66.7) .57
Hypertension 34 (87.2) 27 (81.8) .86
Diabetes
Type 1 5 (12.8) 6 (18.2) .59
Type 2 34 (87.2) 27 (81.8) .86
History of coronary artery diseaseb 16 (41) 8 (24.2) .28
Cerebrovascular accident 6 (15.4) 3 (9.1) .48
COPD 3 (7.7) 1 (3) .42
Smoking history
Current smoker 4 (10.3) 3 (9.1) .88
Previous smoker 18 (46.2) 20 (60.6) .5
Hypercholesterolemia 7 (20) 6 (18.2) .98
History of peripheral vascular diseasec 13 (33.3) 9 (27.3) .68
COPD, Chronic obstructive pulmonary disease; SD, standard deviation.
aPresent at baseline and not at the completion of the study.
bCoronary artery disease is deﬁned as having a history of any of the following: arrhythmia, myocardial infarction, congestive heart failure, previous coronary
revascularization (percutaneous or surgical), angina, or cardiac valvular disease.
cIncludes patients with Rutherford category >1.
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guidelines (access ﬂow <600 mL/min or <1000 mL/min
with >25% decrease during a 4-month period); docu-
mented increased venous pressure during dialysis as deﬁned
by the KDOQI (venous pressure>150mmHg or a trend of
persistent increasing pressure over time); and last, difﬁculty
in ﬁstula cannulation.13 Duplex ultrasound scanning was
used to investigate RCFs that did not mature, to diagnose
problems with ﬁstulas that performed poorly during dialysis,
and to identify whether thrombosed ﬁstula could be revised
or formation of a new ﬁstula or a graft was required.
Statistics. Categorical data are given as counts (per-
centages) and absolute values. Normally distributed
continuous data are expressed as means (or medians) 6
standard deviation. Differences between the groups were
tested for statistical signiﬁcance by the independent t test
for continuous variables and the Pearson c2 test or Fisher
exact test for categorical variables, as appropriate. Estimates
of cumulative event rates were determined by the Kaplan-
Meier method, and differences between groups were
compared by log-rank testing. Patients were censored at
the time of death, renal transplantation, or switch to peri-
toneal dialysis or if no event had occurred on January 31,
2013 (last date of data assessment). Data were analyzed by
the Statistica software (version 7.0; StatSoft, Tulsa, Okla),
with differences being assumed signiﬁcant if the calculated
P value was < .05.
RESULTS
We prospectively enrolled 72 diabetes mellitus patients
with ESRD, either incident or prevalent, who received a
primary RCF at a single vascular center from January
2001 to January 2006. The median age of the study pa-
tients was 66 6 9.3 years (range, 42-83 years). Of these,
56 (77.8%) had already initiated dialysis therapy before cre-
ation of the RCF and were undergoing dialysis with atunneled dialysis catheter. The arm radiograph showed ab-
normality in 39 patients at the site of possible ﬁstula con-
struction (C-group, 47 RCFs), whereas 33 patients had
noncalciﬁed (“healthy”) vascular anatomy (H-group, 40
RCFs). Sixty-one patients (84.7%) had diabetes type 2
(C-group, 87.2%; H-group, 81.8%; P ¼ .86). The groups
did not differ in a statistically signiﬁcant level in terms of
age at ﬁstula placement, sex, type of diabetes mellitus, hy-
pertension, history of peripheral vascular disease, or cardio-
vascular disease. Characteristics of the dialysis population
groups are given in Table I. The majority of patients in
both groups were men (P ¼ .57).
Mean diabetic disease duration at the time of RCF
creation was 8.9 6 5.6 years (range, 2-25 years) for the
H-group and 14 6 9.9 years (range, 1-40 years) for the
C-group (P ¼ .018). All access procedures were performed
under local anesthesia. Most of the primary RCFs (w80%)
and all revisions were constructed by a single vascular sur-
geon (G.S.G.). No antibiotics were used except in cases in
which a short interposition polytetraﬂuoroethylene graft
was required for type 1 or type 2 ﬁstula stenosis revision.14
The technical success rate was 95.8% and 95% for the
C-group and H-group, respectively. Table II summarizes
preoperative and intraoperative RCF details. The proce-
dure times were signiﬁcantly longer in C-group (57 vs
50 minutes; P < .05). In the majority of patients in both
groups, the ﬁrst cannulation of the superﬁcially located ce-
phalic vein was possible within 30 to 40 days after the pri-
mary operation. In revised cases, ﬁstula cannulation was
performed in the next hemodialysis session. Eleven patients
(H-group, 8 [24.2%]; P ¼ .1) had more than one RCF
created, and these additional ﬁstulas were created in the
other arm or more proximal to the initial ﬁstula. The
mean time that passed between creation of another ﬁstula
was 12.6 months. In two of these H-group patients, the
original ﬁstula was not used for dialysis.
Table II. Perioperative primary radiocephalic ﬁstula (RCF) details
Variable C-group, No. (%) H-group, No. (%) P value
Primary RCF 47 40 .99
Patients receiving >1 RCF 5/39 6/33 .59
Medial sclerosis
Antebrachial arteries 32 NA NA
Antebrachial arteries þ brachial bifurcation 7 NA NA
Cephalic vein diameter, mm, mean 6 SD (range) 2.28 6 0.36 (1.6-3.1) 2.41 6 0.44 (1.7-3.2) .12
Cephalic vein diameter $2 mm 37/47 (78.7) 34/40 (85) .81
Radial artery diameter, mm 2 6 0.28 (1.5-2.7) 2.1 6 0.4 (1.5-2.8) .27
Suture used
6-0 Prolene 11 (23.4) 18 (45) .13
6-0 PTFE 4 (8.5) 3 (7.5) .87
7-0 Prolene 26 (55.3) 23 (57.5) .91
Operation time, minutes, mean 6 SD (range) 57 6 6.38 (40-72) 50 6 7.93 (36-69) <0.05
Technical success 45/47 38/40 .98
Nonthrombotic complications
Minor hematoma 2/47 0 .2
Skin erythema 1/47 0 .36
NA, Not applicable; PTFE, polytetraﬂuoroethylene; SD, standard deviation.
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C-group vs H-group were 50.2% vs 80%, 36.5% vs 72.3%,
32.4% vs 67.9%, and 29.1% vs 59.3% (P ¼ .0019; Fig 2).
Respective values for secondary patency rates were 52.4%
vs 87.5%, 40.9% vs 82.4%, 36.6% vs 78.1%, and 33.2% vs
72.8% (P ¼ .00064; Fig 3).
A cutoff point of $10 years for diabetic disease dura-
tion did not inﬂuence primary patency rates in both
groups. Mean survival times were 62 6 33.2 months
(range, 12-126 months) and 31.5 6 33.1 months (range,
1-144 months) for H-group and C-group, respectively
(P ¼ .0002). There was a trend toward higher mortality
rates in the C-group, and this trend reached marginally sta-
tistical signiﬁcance (P ¼ .05). Speciﬁcally, survival rates at
12, 24, 36, 48, and 60 months were 75.3%, 56.1%,
48.6%, 46.4%, and 37.1% for C-group and 98.5%, 92.4%,
73.9%, 67.4%, and 65.6% for H-group, respectively.
Cumulative patient survival rates are shown in Fig 4.
At the completion of the study, only 17 patients
(C-group, 7 of 39 [18%]; H-group, 10 of 33 [30.3%];
P ¼ .34) were still on hemodialysis with a primary or
revised RCF (17 of 87 RCFs; 19.5%). Of these RCFs, 15
(17.2%) were located in the same extremity. At the end
of follow-up, 11 patients (15.3%) were still living with a
functioning new autogenous or prosthetic vascular access
in the ipsilateral or contralateral arm. The remaining died
(n ¼ 44; 61.1%) for reasons unrelated to the vascular ac-
cess. More diabetic C-group patients had died (n ¼ 23;
P ¼ .84). Two C-group patients (5.1%) had been switched
to peritoneal dialysis, whereas one patient from each group
(2.6% vs 3.3%) had received a renal transplant.
Overall mean follow-up was 38 months. The mean
follow-up period for H-group and C-group was 51.9 6
35.6 months (range, 0.1-126 months) and 26.1 6
31.6 months (range, 0.1-144 months), respectively (P ¼
.0006). Follow-up covered 275.3 patient-years at risk
(mean per patient, 3.8 years), that is, 172.9 years for theH-group (mean, 5.2 years) and 102.4 years for the
C-group (mean, 2.6 years).
Failure of RCFs to mature, leading to cannulation
problems, was observed in four patients (three in C-group),
mainly from low arterial blood ﬂow because of narrowing
of the feeding radial artery or failure of venous dilation to
occur. Revision operations were possible in 12 patients
(C-group, four; H-group, eight; P ¼ .15) primarily to cor-
rect clinically relevant, late, and short in length type 1 vein
stenosis (juxta-anastomotic). RCF construction in a more
proximal level was the most frequently performed revision.
In the remaining patients, second-step operations were per-
formed (superﬁcialization of the basilic vein in the antebra-
chial region, prosthetic or composite antebrachial loop
graft, prosthetic brachial C-graft, or superﬁcialization of
the basilic vein in the upper arm) according to cephalic
vein status (absent or of insufﬁcient caliber). No diabetic
patient required revision to correct a steal syndrome. Early
RCF thrombosis (<4 weeks) occurred in ﬁve RCFs, three
of them in C-group (6.4%; P ¼ .79; Table III). Poor
outﬂow veins and narrow feeding artery had been noted
during surgery in all ﬁve cases.
DISCUSSION
Autogenous ﬁstula creation in the diabetic is still a spe-
cial and demanding problem in vascular access surgery.
Contradictory results of the efﬁcacy of RCF in diabetics
have been reported; some authors suggested that RCF
patency is poorer,15 whereas others have found no ef-
fect.16,17 Although, in general, RCFs have reported sec-
ondary patency rates of 64% to 72% and 37% to 72% at
3 and 5 years, respectively,16 earlier disappointing results
of successful RCF creation in diabetics, with only 48.5%
initial success rate18 and 31.5% incidence of early throm-
bosis,19 supported the recommendation of creating pros-
thetic instead of autogenous ﬁstulas to avoid frustrating
attempts at wrist level.20 Ernandez et al21 found that
Fig 2. Primary patency rates of radiocephalic ﬁstulas (RCFs) comparing H-group and C-group patients. SE, Standard error.
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patients. However, others3 have not reported statistically
signiﬁcant primary patency rates in autogenous ﬁstulas
(w60% RCFs), at 12 and 24 months, respectively, in dia-
betic vs nondiabetic patients, for men younger than
65 years (70% vs 85% and 61% vs 75%, respectively),
women younger than 65 years (69% vs 67% and 62% vs
51% respectively), men older than 65 years (81% vs 77%
and 72% vs 68%, respectively), or women older than
65 years (78% vs 73% and 70% vs 63%, respectively). Of in-
terest, no diabetic patient had suffered from early
(<4 weeks) thrombosis.3 Furthermore, Lin et al2 have
shown that diabetes is not associated with primary failures
of RCFs, and Sedlacek et al22 noted that diabetics are as
good candidates for RCF as patients without diabetes,
although in the latter study, patients with diabetes had a
greater prevalence of vascular calciﬁcations and greater
cuff measurements of systolic segmental arterial pressure.
This conﬂicting evidence as to whether diabetes is an
adverse factor of access patency, especially for distal
RCFs, strengthens the results of the present study, which
showed that the long-term beneﬁt of RCFs, regarding pri-
mary and secondary patency rates, may be lost in diabetics
with calciﬁed radial arteries compared with those with
healthy vessels. It is unlikely that our results were affectedby the smaller diameter of the cephalic veins because our
threshold for RCF creation was above 1.6 mm, and im-
portantly, most patients in C-group and H-group had
$2-mm vein diameter (w78% vs 85%, respectively). In
addition, most of the procedures were performed by a
single surgeon, thus establishing uniformity of technique
and minimizing bias. We found also that mean diabetic
disease duration at RCF placement was signiﬁcantly higher
in the worse C-group, suggesting that possibly longer
periods of vascular damage might play a pivotal role in
long-term RCF failure. Taking also into consideration
the highest mortality rate we observed in this group,
RCF construction as a ﬁrst vascular access option may be
questionable in patients with calciﬁed distal arm arteries
and limited life expectancy.
In vascular access surgery, special attention has been
paid to the availability of suitable diameter and patency of
the superﬁcial arm vein, but the quality of the arterial
wall and the diameter of the arterial lumen are of similar
importance. After the creation of a primary RCF, a consid-
erable increase in blood ﬂow results in progressive enlarge-
ment of arteries and veins23 and also cephalic vein wall
remodeling, such as thickening and decreased tendency
to spasm, a process called ﬁstula maturation.24,25 Thus,
construction of the RCF in patent and not stenotic cephalic
Fig 3. Secondary patency rates of radiocephalic ﬁstulas (RCFs) comparing H-group and C-group patients.
SE, Standard error.
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inﬂow the only parameter to support dialysis. However, di-
abetics commonly display medial calciﬁcation of peripheral
arteries, known as Mönckeberg sclerosis, to such an extent
that when it is hemodynamically signiﬁcant, it hinders the
maturation process by preventing the compensatory hyper-
trophy of the feeding artery and the subsequent increase in
the arterial ﬂow.20,26 A recent study examining medial
ﬁbrosis and microcalciﬁcation scores in patients with
mature and nonmaturing ﬁstulas (all autogenous options)
reported a trend toward greater microcalciﬁcation in non-
maturing ﬁstulas.10 It remains unclear whether microcalci-
ﬁcations, frequently observed in arteries used to create
arteriovenous ﬁstulas,10 are as clinically important as mac-
rocalciﬁcations in speciﬁc locations like the wrist.
Apart from the maturation process, ﬁstula patency is
also an important issue. In one report, pre-existing arte-
rial intimal hyperplasia was associated with decreased ﬁs-
tula patency.27 However, in another recent study, neither
arterial nor venous pre-existing increased intimal thick-
ness was associated with inferior unassisted primary arte-
riovenous graft patency.28 In the same study, factors
contributing to arterial stiffness, thereby increasing shear
stress, like medial ﬁbrosis and calciﬁcation, were not
found to accelerate neointimal hyperplasia as expected
and did not shorten arteriovenous graft patency.28However, no study has so far evaluated the impact of
pre-existing radial artery macrocalciﬁcations on RCF
patency rates purely in a diabetic population. In this
study, we have shown that in a diabetic (mostly type 2)
population, primary RCF does not work equally between
patients with highly calciﬁed arteries and patients with
healthy arteries. Primary and secondary failures were sta-
tistically higher in C-group patients, suggesting that RCF
creation may not be the best option in these patients.
Although proximal arteries are less affected in diabetics
because of a centripetal atherosclerotic pattern3 and
medial wall calciﬁcations are infrequent in the brachial ar-
tery,26 and despite the fact that elbow ﬁstulas cause more
steal syndrome3 and cardiac failure,2 it is believed that
the formation of a brachiocephalic ﬁstula as a primary
procedure may be more preferable in terms of patency
and rate of maturation.3,29 Extending these observations
to what we have found, that RCFs in diabetic patients
with calciﬁed radial vessels had worse primary patency
rates than their diabetic counterparts with healthy vessels,
we strongly recommend that patients with extensively
calciﬁed radial arteries be treated with brachiocephalic
ﬁstulas and not RCFs. Thus, the preferred type of perma-
nent vascular access for all diabetic patients with ESRD
may not be as straightforward as described in the
KDOQI clinical practice guidelines.13
Fig 4. Cumulative patient survival rates comparing H-group and C-group patients. SE, Standard error.





No. (%) P value
Early RCF thrombosis
(#1 month)
3/47 (6.4) 2/40 (5) .79
Failure to maturea 3/44 (6.8) 1/38 (2.6) .4




New RCF proximally 2 5
Vein antebrachial loop 1
Cephalic vein PTFE patch 1
Second-step operations 7/39 (18) 4/33 (12.1) .56
PTFE, Polytetraﬂuoroethylene.
aExcluding cases with early thrombosis.
bFor concomitant stenosis-aneurysm lesion.
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cess is its functional length of survival (secondary patency),
although complication rates and ease of use are of similar
importance.30 Surprisingly, no information is available
with which we could compare our results regarding RCFs
in diabetic patients with calciﬁed arm vessels. Our results
are different from those observed by other experienced
vascular access surgeons reporting identical primary
patency rates in nondiabetic and diabetic patients, and
this was true both for wrist/forearm and for elbow ﬁs-
tulas.3 Rooijens et al31 pooled primary patency, secondary
patency, and primary failure data from studies carried out
from 1970 to 2002 and found that besides moderate pri-
mary and secondary patency rates at 1-year follow-up
(62.5% and 66%, respectively), the pooled estimate primary
failure was 15.3%. In this study, although both cohorts
were diabetics, we described higher primary and secondary
patency rates at 12 months, but only for the healthy vessel
H-group, suggesting that calciﬁed vessels might have
contributed to these lower outcomes. However, we had a
lower early failure rate in both groups (<7%), suggesting
that other patient characteristics, including age and gender,
might inﬂuence the results.
Male gender, diabetes mellitus, and dialysis vintage
have been reported as risk factors for vascular accesscalciﬁcation (VAc).8 Furthermore, VAc could be a marker
of systemic vascular calciﬁcation. It has been shown that
patients with VAc had increased iliac/femoral calciﬁcation
and a trend toward more frequent carotid or cardiac valve
calciﬁcations.8 Another study showed that patients with
arterial VAc scores >10% had more frequent peripheral
vascular disease compared with those with <10% VAc
scores.28,32 Previous studies6,8,9 have shown that vascular
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Volume 60, Number 2 Georgiadis et al 469calciﬁcation is an important risk factor for death in dialysis
patients. Schlieper et al8 reported lower mean cumulative
survival rates in patients with VAc compared with those
without VAc (946 vs 1089 days). Of interest, diabetics
had a 3.43-fold risk for VAc compared with nondiabetics.
Similarly, Wang et al32 reported that cardiac valve calciﬁ-
cation is a powerful predictor for mortality and cardiovas-
cular deaths in long-term dialysis patients. In agreement
with these studies, diabetic C-group patients with severe
VAc had signiﬁcantly higher mortality rates than those
diabetics with healthy vessels. Thus, in considering RCF
creation in diabetics on dialysis with severe VAc, their sur-
vival (50% at 3 years and 30% at 5 years)20 should not be
overlooked.
There are some limitations of our study. First, it repre-
sents the experience of a single center and may not be
generalizable to that at other centers. Second, the radio-
graphic method to detect calciﬁcations was a simple X
ray technique; thus, we might have missed early stages of
calciﬁcation (microcalciﬁcations) and mild media wall ri-
gidity in patients with apparently healthy vessels. Although
calciﬁcation is detectable by computed tomography, this
was not part of the study protocol. Furthermore, there
may be additional pathologic abnormalities in the native
arteries or veins that are deﬁnitely not detected by simple
radiographs.
CONCLUSIONS
The ﬁndings of this study suggest that creation of the
RCF in the face of signiﬁcant radial artery calciﬁcation
has poor outcome and therefore should be avoided.
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